Altermune Technologies LLC
www.altermune.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altermune Technologies LLC
Venture Funding Deals, February 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
Deal Watch: Acorda Places Another Bet In Neurology With Biotie Tender
Following the dissolution of its partnership with Sanofi, MannKind's next gambit is licensing its dry-powder delivery technology to new company Receptor Life Sciences. We also highlight our sister publication IN VIVO's deal of the year winners in the alliance, M&A and financing categories.
Selected Start-Ups (10/2011)
In Vivo briefly describes these recently founded companies: Altermune Technologies, Ariel Pharmaceuticals, AUM Cardiovascular, BioMoti, Tensha Therapeutics and Trevi Therapeutics.
Recent Financings of Private Companies (10/2011)
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice